Vir: Data Shows Sotrovimab Retains Neutralizing Activity Aga

LONDON (dpa-AFX) - Vir Biotechnology Inc. (VIR) said pre-clinical data suggested that sotrovimab, an investigational monoclonal antibody authorized for emergency use in the United States and developed

Related Keywords

United States , London , City Of , United Kingdom , , Glaxosmithkline , Vir Biotechnology Inc , Data , Shows , Otrovimab , Etains , Neutralizing , Activity , Against , Micron , Ubvariant ,